PEPCLUB.me

Weight ManagementArticlePremium

AOD-9604

5mg Vial

29 August 2026Updated 29 August 2026

AOD-9604

Overview Research7

Mechanism Protocols Safety Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for AOD-9604.

Create free account Member login

Full range of benefits for AOD-9604

Stimulates lipolysis (fat breakdown) in preclinical and some clinical studies

Inhibits lipogenesis (fat creation) in adipose tissue models

Enhances fatty-acid oxidation in adipocytes in preclinical research

Minimal activation of systemic GH/IGF-1 pathways at studied doses

Shown to reduce triglyceride accumulation in animal and pilot studies

Investigated as an adjunct to diet/exercise for body composition

Preclinical evidence of potential chondroprotective / cartilage effects

Generally well tolerated in short-term clinical safety studies

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

7 Published Studies

Scientific literature related to AOD-9604 and its potential applications.

Abstract analysed

Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.

In obese Zucker rats, oral AOD9604 (500 µg/kg/day for 19 days) markedly reduced weight gain and increased adipose tissue lipolytic activity without detectable worsening of insulin sensitivity by euglycemic clamp; however, the evidence is limited to an abstract-level animal study with incomplete reporting.

Dose-response studies and lower/higher dose evaluationLonger-term efficacy and safety studies in animalsPharmacokinetics and bioavailability after oral dosing+3 more

Relevance

100%

Source

Europe PMC, PubMed

DOI: 10.1159/000053183

Published

2000

Abstract analysed

Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.

The authors present a streamlined single-extraction LC-HRMS workflow capable of detecting 54 prohibited peptidic and non-peptidic agents with satisfactory group-level validation metrics; AOD-9604 was specifically found to be extensively degraded in serum and plasma after one week at 4 and 22 °C but remained detectable in dried blood matrices, supporting dried-sample logistics for doping control.

Analytical method developmentDoping control testingPeptide detection in blood matrices+3 more

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.1039/d6an00455e

Published

2026

Full text analysed

Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.

Co-loading hGH fragment 176–191 peptide (AOD-9604) with doxorubicin into chitosan nanoparticles produced nanoparticles with favorable physicochemical properties and yielded modestly greater in vitro cytotoxicity against MCF-7 cells compared with doxorubicin alone or DOX-loaded chitosan nanoparticles; in silico docking suggests the peptide can alter doxorubicin binding to several breast cancer proteins, providing a proposed mechanism.

In vivo efficacy and safety studies (animal models) to test therapeutic benefit and systemic toxicity.Quantification of entrapment efficiency and drug loading for Ch-hGH-DOX nanoparticles.In vitro and in vivo drug release kinetics and stability of nanoparticles.+4 more

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.2147/dddt.s367586

Published

2022

Abstract analysed

Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.

In this collagenase-induced rabbit knee OA model, intra-articular AOD9604 improved cartilage morphology and histopathology compared with saline, and combining AOD9604 with hyaluronic acid produced greater structural and functional benefit than either agent alone. Results are preliminary and limited to a small preclinical study reported in abstract form.

Osteoarthritis (preclinical)Intra-articular peptide therapyCartilage regeneration+1 more

Relevance

100%

Source

Europe PMC, PubMed

PMID: 26275694

Published

2015

Abstract analysed

Detection and in vitro metabolism of AOD9604.

AOD9604 can be detected in urine at low pg/mL levels using a validated solid-phase extraction method (LOD 50 pg/mL); six metabolites were identified in vitro after incubation in serum and urine, and one serum metabolite (CRSVEGSCG) is notably more stable than the parent peptide — screening for this metabolite alongside the parent compound could potentially extend the detection window, but evidence is limited to in vitro data.

Anti-doping analytical method developmentPeptide metabolism (in vitro)Analytical chemistry (peptide detection in biological matrices)

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.1002/dta.1715

Published

2015

Abstract analysed

Current updates in the medical management of obesity.

AOD9604 is mentioned in this review abstract as a recent anti-obesity patent/agent that may reduce adiposity at the molecular level, but the abstract provides no experimental, clinical, dosing, efficacy, or safety data.

Mechanistic evaluation of how listed agents (including AOD9604) reduce adiposity at the molecular levelClinical trials to assess efficacy and safety of AOD9604 in humans with obesityComparative effectiveness of emerging anti-obesity agents versus approved therapies

Relevance

80%

Source

Europe PMC, PubMed

DOI: 10.2174/187221412800604644

Published

2012

Abstract analysed

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.

In obese mice, chronic intraperitoneal treatment with hGH or AOD9604 reduced body weight and fat and increased beta3-AR RNA expression; these chronic effects were absent in beta3-AR knock-out mice, but AOD9604 produced acute increases in energy expenditure and fat oxidation even in knock-outs—supporting that the lipolytic actions are not directly mediated by beta3-AR, although upregulation of the receptor may enhance lipolytic sensitivity.

Peptide-mediated lipolysisRole of beta3-adrenergic receptor in adipose tissue lipolysisMetabolic effects of growth hormone fragments+1 more

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.1210/endo.142.12.8522

Published

2001